J
J G Cairncross
Researcher at Duke University
Publications - 4
Citations - 2506
J G Cairncross is an academic researcher from Duke University. The author has contributed to research in topics: Anaplastic astrocytoma & Diaziquone. The author has an hindex of 4, co-authored 4 publications receiving 2429 citations.
Papers
More filters
Journal ArticleDOI
Response criteria for phase II studies of supratentorial malignant glioma.
TL;DR: This work suggests "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications, to minimize misinterpretations of response.
Journal ArticleDOI
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas
Michael Glantz,Peter C. Burger,James E. Herndon,Allan H. Friedman,J G Cairncross,Nicholas A. Vick,S. C. Schold +6 more
TL;DR: A difference in histologic diagnoses in a consecutive series of 329 patients with newly diagnosed anaplastic gliomas whose diagnoses were established by either stereotactic biopsy or open resection suggests that some AAs diagnosed by stereotaxis biopsy are actually glioblastomas and has important implications for the design and interpretation of clinical trials.
Journal ArticleDOI
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
S. C. Schold,James E. Herndon,Peter C. Burger,Edward C. Halperin,Nicholas A. Vick,J G Cairncross,D R Macdonald,E J Dropcho,R. Morawetz,Darell D. Bigner +9 more
TL;DR: There was no significant difference in efficacy between AZQ and BCNU in patients with anaplastic gliomas as tested in this study, although AZQ was somewhat better tolerated.
Journal ArticleDOI
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
S. C. Schold,M S Mahaley,Nicholas A. Vick,Henry S. Friedman,Peter C. Burger,Elizabeth R. DeLong,Robert E. Albright,Dennis E. Bullard,Janardan D. Khandekar,J G Cairncross +9 more
TL;DR: It is concluded that these AZQ-based regimens have activity in patients with recurrent anaplastic gliomas, but that they are not clearly superior to other agents in current use.